Driven by Science.
Powered by Purpose.
Explore the future of TCR-T therapy with our CEO, Rachel, sharing our mission, vision, and the impact of our technology on patients’ lives.
At Pan Cancer T, we are transforming the landscape of cancer treatment with the power of adoptive cell therapy. By focusing on unique cancer-specific targets, we aim to extend the reach of T cell therapies to new patient populations. Our proprietary next-generation gene engineering enhances T cell fitness, designed to prolong the duration of clinical responses.
Treating solid tumours remains one of oncology’s greatest challenges. Conventional therapies often fall short due to the difficulty of identifying precise targets and the complexity of tumour defences.
We bring new hope to patients facing the most difficult diagnoses by redefining cancer treatment. Our innovative TCR-T technology platform harnesses the power of patients’ own immune cells to fight their cancer by training the T cells to recognise solid tumours with unprecedented precision. With our next-generation gene engineering platform, we enhance T cell fitness and persistence—designed to deliver longer-lasting clinical responses.
UNIQUE ANTIGENS
Our portfolio includes validated, untapped cancer-specific intracellular targets—powerfully expressed in some of the most challenging solid tumours, yet absent in healthy tissues.
UNMATCHED PRECISION
Our platform finds naturally occurring, optimal affinity TCRs that specifically target cancer cells. This allows us to engineer safer, more precise treatments that attack cancer while minimizing cross-reactivity and safety concerns.
OVERCOMING TUMOUR DEFENSES
We go beyond simply targeting cancer cells. By counteracting immune suppression within the tumour microenvironment, we aim to boost T cell longevity and extend clinical responses, ensuring our therapies make a lasting impact.